TrialPloS one2016

Octreotide LAR and Prednisone as Neoadjuvant Treatment in Patients with Primary or Locally Recurrent Unresectable Thymic Tumors: A Phase II Study.

Lukas Kirzinger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.